| abstract |
Disclosed is use of native human protein C for production of pharmaceutical preparation for prevention and treatment of deposition and/ or aggregation of thrombocytes, microparticles of thrombocytes, particularly in the form of powder, and leucocytes with procoagulating activity on the vessel surface and/ or vessel stenosis, particularly on injured, virus infected or injured endothelium or on the uncovered sub-endothelium, or on the synthetic vessel surface or on vessel replacements with or without endothelium. Disclosed is also method for prevention of deposition and/ or aggregation of thrombocytes in vitro, wherein an effective amount of native human protein C is added. |